Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 6Stomach Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 2HER2-positive Gastric Cancer 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Muscle Invasive Bladder Carcinoma 1Muscle Invasive Bladder Cancer (MIBC) 1Muscle Invasive Bladder Cancer 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Lung Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1HER2-low Breast Cancer 1HER2 1Gastric Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Breast Cancer 1

Interventions

Oxaliplatin 270Bevacizumab 260Fluorouracil 249Irinotecan 240Leucovorin 218Capecitabine 196Cetuximab 161Colonoscopy 74Folfox protocol 70Panitumumab 64regorafenib 62Drug Therapy 52Radiotherapy 50HMPL-013 50Blood Specimen Collection 45trifluridine tipiracil drug combination 43pembrolizumab 41Surveys and Questionnaires 35Standard of Care 35Nivolumab 34Neoadjuvant Therapy 34Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 31IFL protocol 27Trifluridine 26Interviews as Topic 26Celecoxib 26XELOX 25Early Intervention, Educational 24Specimen Handling 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Colorectal Neoplasms × disitamab vedotin × Clear all
NCT05578287 2023-12-07

DETECT

Sun Yat-sen University

Phase 2 Unknown
29 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05493683 2022-10-21

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
29 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05333809 2022-04-20

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Shanghai Zhongshan Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡